A. Staddon

发表

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

J. Machiels, L. Dirix, Sunil Sharma, 2014, Cancer Chemotherapy and Pharmacology.

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma

E. Stepanski, M. Milhem, D. Priebat, 2017, Cancer.

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Robin L. Jones, S. Steinberg, D. Reinke, 2020, Sarcoma.

Recurrent Osteosarcoma Localized to the Lung

Robin L. Jones, E. Kleinerman, S. Schuetze, 2020 .

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

David M. Thomas, J. Blay, M. Roudier, 2010, The Lancet. Oncology.

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

David M. Thomas, J. Blay, P. Rutkowski, 2013, The Lancet. Oncology.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Robin L. Jones, B. Monk, G. Demetri, 2017, Gynecologic oncology.

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.

H. Burris, K. Mettinger, H. Gerstein, 2005, The oncologist.

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy

M. Millenson, H. Borghaei, C. Langer, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

A. Hendifar, S. Chawla, R. Patwardhan, 2013, BMC Cancer.

Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature

A. Staddon, Trisha M. Plastini, 2017, Case reports in medicine.

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

L. Dirix, G. Manikhas, T. Parekh, 2011, Cancer Chemotherapy and Pharmacology.

Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial

J. Blay, G. Demetri, A. Tolcher, 2007 .

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study.

J. Blay, M. Roudier, S. Chawla, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study

David M. Thomas, J. Blay, M. Roudier, 2008 .

A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Robin L. Jones, G. Demetri, H. Tawbi, 2015 .

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Robin L. Jones, G. Demetri, H. Tawbi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

Robin L. Jones, B. Monk, G. Demetri, 2016 .

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

J. Blay, S. Ferrari, H. Gelderblom, 2012, Sarcoma.

Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients

M. Rudnick, J. Tomaszewski, Amir Haghighat, 1995, Cancer.

Early Outcomes for Malignant Peripheral Nerve Sheath Tumor Treated With Chemotherapy

R. Lackman, A. Staddon, V. Moretti, 2011, American journal of clinical oncology.

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

J. Blay, G. Demetri, A. Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

J. Blay, G. Demetri, A. Tolcher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

R. Lackman, H. Haupt, J. Brooks, 2008, Modern Pathology.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

H. Tawbi, V. Bolejack, D. Reinke, 2017, Cancer.

Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma

J. Shrager, S. Sonnad, L. Kaiser, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osteogenic sarcoma presenting with lung metastasis.

J. Shrager, A. Staddon, M. Warhol, 2002, The oncologist.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2012, The Lancet.

Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development

R. Sebro, J. Shabason, A. Staddon, 2019, Cancer medicine.

SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017 .

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

J. Blay, Ruey-min Lee, G. Demetri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017, Sarcoma.

Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.

K. Ganjoo, S. Schuetze, M. Mehren, 2010 .

Phase I/IIa, randomized, open-label, drug-drug interaction study of trabectedin and rifampin in patients with advanced cancer.

Sunil Sharma, R. Knoblauch, T. Parekh, 2013 .

Combined Sclerosing and Spindle Cell Rhabdomyosarcoma in Previous Craniotomy Site: A Case Report and a Review of the Literature

E. Zager, Paul J. L. Zhang, S. Nagda, 2018, International journal of surgical pathology.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

J. Blay, G. Demetri, T. Clackson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection

C. Simone, K. Weber, S. Hahn, 2016, Journal of surgical oncology.

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.

J. Blay, A. Santoro, P. Hohenberger, 2014, European journal of cancer.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Blay, G. Demetri, A. Tolcher, 2015, The Lancet. Oncology.

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

A. Hendifar, S. Chawla, R. Patwardhan, 2013, BMC Cancer.

An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide.

S. Chawla, Y. M. Kamel, C. Messam, 2010 .

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

Dafydd G. Thomas, V. Bolejack, D. Reinke, 2018, JAMA oncology.

Challenges of ensuring adherence to oral therapy in patients with solid malignancies

A. Staddon, 2011 .

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

P. Frankel, M. Milhem, S. Okuno, 2019, Cancer.

Agranulocytosis associated with yohimbine use.

A. Staddon, M. Siddiqui, D. More-O'Ferrall, 1996, Archives of internal medicine.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

Dafydd G. Thomas, J. Wathen, H. Tawbi, 2016, Cancer.

A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

M. von Mehren, S. Schuetze, M. Mehren, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

J. Blay, I. Judson, L. Jönsson, 2016, European journal of cancer care.

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

J. Blay, J. Verweij, I. Judson, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

"Residual Osteocytic Lesion": Effect of Denosumab (AMG 162) Treatment on the Morphology and Immunophenotype of Giant-Cell Tumor: A Report of Two Cases.

J. Brooks, A. Staddon, N. Riddle, 2013, JBJS case connector.

SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).

S. Steinberg, D. Reinke, S. Schuetze, 2013 .

Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity

C. Simone, K. Weber, T. Delaney, 2020, Journal of surgical oncology.

Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

J. Blay, G. Demetri, A. Italiano, 2013 .

Treatment of Adult Rhabdomyosarcoma

R. Lackman, L. Hartner, R. Slotcavage, 2007, American journal of clinical oncology.

Chronic low dose-intensity pegylated liposomal doxorubicin for advanced malignancies

S. Kilcoyne, D. Henry, A. Staddon, 2007 .

Utility of PET scan in predicting chemotherapeutic response in soft tissue sarcoma patients

A. Alavi, D. Mintzer, R. Lackman, 2007 .

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study

C. Cleeland, K. Ganjoo, I. Jacobs, 2014, Acta oncologica.

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

J. Crowley, D. Reinke, R. Benjamin, 2010 .

Abstracts of the 2011 International MASCC/ISOO Symposium

C. Cleeland, I. Jacobs, S. Stacchiotti, 2011, Supportive Care in Cancer.

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

J. Crowley, D. Reinke, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).

J. Blay, A. Cesne, A. D. Dei Tos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Embedding palliative care and geriatric oncology within a private oncology practice: one model for success

D. Mintzer, L. Hartner, M. Lynch, 2009 .

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN).

D. Hayes, J. Grilley-Olson, C. Langer, 2013 .

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study

C. Cleeland, K. Ganjoo, I. Jacobs, 2014, Acta oncologica.

Treatment of Adult Rhabdomyosarcoma

R. Lackman, L. Hartner, R. Slotcavage, 2009, American journal of clinical oncology.

Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.

J. Blay, G. Demetri, A. Cesne, 2012 .

Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma

J. Shrager, S. Sonnad, L. Kaiser, 2011, Journal of Thoracic Oncology.

PALETTE : Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients

J. Blay, A. Cesne, P. Hohenberger, 2012 .